Epigenomics AG, DE000A11QW50

Epigenomics AG, DE000A11QW50

14.11.2016 - 17:50:28

Epigenomics AG to participate in investor conferences

Press release

Epigenomics AG to participate in investor conferences

Berlin (Germany) and Germantown, MD (U.S.A.), November 14, 2016 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) today announced that Greg Hamilton, Chief Executive Officer, will participate in the following investor conferences:

- Canaccord Genuity Medical Technologies & Diagnostics Forum, Thursday November 17, 2016, New York, Westin New York Grand Central, Presentation: 10:00 am (EST)

- German Equity Forum 2016, Tuesday, November 22, 2016, Frankfurt, Sheraton Frankfurt Airport Hotel, Presentation: 5:00 PM (CET)

- goetzpartners Interdisciplinary Oncology Insight Symposium, November 29, 2016, London, Le Meridien Piccadilly, Panel discussion: 2:00 PM (GMT)

About Epigenomics Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.

For more information, visit www.epigenomics.com.

Contact Epigenomics AG

Peter Vogt Vice President Corporate Communications & Investor Relations Epigenomics AG Geneststraße 5 10829 Berlin Phone +49 (0) 30 24345 386 ir@epigenomics.com

http://www.epigenomics.com

14.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Epigenomics AG Geneststraße 5 10829 Berlin Germany Phone: +49 30 24345-0 Fax: +49 30 24345-555 E-mail: ir@epigenomics.com Internet: www.epigenomics.com ISIN: DE000A11QW50 WKN: A11QW5 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service

520649 14.11.2016

@ dgap.de